Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Contents
- •1.1 Introduction
- •1.2 Pathophysiology
- •1.3 Case Presentation
- •1.4 Case Discussion
- •1.5 Clinical Characteristics
- •1.6 Diagnostic Algorithm
- •1.8 Management
- •1.9 Conclusion
- •References
- •2.1 Introduction
- •2.2 Pathophysiology
- •2.3 Case Presentation
- •2.4 Case Discussion
- •2.5 Clinical Characteristics
- •1.7 Differential Diagnosis
- •2.6 Diagnostic Algorithm
- •2.7 Management
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Pathophysiology
- •3.3 Case Presentation
- •3.4 Case Discussion
- •3.5 Clinical Characteristics
- •3.6 Diagnostic Algorithm
- •3.7 Management
- •3.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Pathophysiology
- •4.3 Case Presentation
- •4.4 Case Discussion
- •4.6 Diagnostic Algorithm
- •4.7 Management
- •4.8 Conclusion
- •References
- •5.1 Introduction
- •5.2 Pathophysiology
- •5.3 Case Presentation
- •5.4 Case Discussion
- •5.5 Diagnostic Algorithm
- •5.6 Management
- •5.7 Conclusion
- •References
- •6.1 Introduction
- •6.2 Pathogenesis
- •6.3 Case Presentation
- •6.4 Case Discussion
- •6.5 Diagnostic Algorithm
- •6.6 Management
- •6.7 Conclusion
- •References
- •7.1 Introduction
- •7.2 Pathophysiology
- •7.3 Case Presentation
- •7.5 Differential Diagnosis
- •7.7 The Following Strategies Are Essential
- •7.7.1 Acute Symptom Relief
- •7.7.1.1 Pharmacological Treatment
- •7.7.2.1 Pharmacologic Prophylaxis
- •7.8 Conclusion
- •References
- •8.1 Introduction
- •8.3 Case Study
- •8.4 Case Discussion
- •8.5 Clinical Management
- •8.7 Diagnosis
- •8.8 Treatment
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Case Presentation
- •9.4 Diagnosis Algorithm
- •9.5 Secondary SUNCT
- •9.6 Management
- •9.8 Conclusion
- •References
- •10.1 Introduction
- •10.2 Pathophysiology
- •10.3 Case Presentation
- •10.4 Case Discussion
- •10.5 Clinical Characteristics
- •10.6 Diagnostic Algorithm
- •10.7 Management
- •10.8 Conclusion
- •References
- •11.1 Introduction
- •11.2 Pathophysiology
- •11.3 Case Presentation
- •11.4 Case Discussion
- •11.5 Clinical Characteristics
- •11.6 Diagnostic Algorithm
- •11.6.1 Step 1: Detailed Patient History
- •11.8 Management
- •11.9 Conclusions
- •12.2 Pathophysiology
- •12.3 Case Presentation
- •12.4 Case Discussion
- •12.6 Treatment
- •12.7 Conclusion
- •References
- •References
- •12.1 Introduction
- •13.1 Introduction
- •13.2 Pathophysiology
- •13.3 Case Presentation
- •13.4 Case Discussion
- •13.5 Clinical Characteristics
- •13.6 Diagnostic Algorithm
- •13.7 Management
- •13.8 Conclusion
- •References
- •14.1 Introduction
- •14.2 Pathophysiology
- •14.3 Case Presentation
- •14.3.1 Clinical Case 1
- •14.3.2 Clinical Case 2
- •14.4 Case Discussion
- •14.5 Clinical Characteristics
- •14.7 Treatment/Management
- •14.8 Conclusion
- •References
- •15.1 Introduction
- •15.2 Case Presentation
- •15.3 Case Discussion
- •15.4 Diagnostic Algorithm
- •15.5 Pathophysiology
- •15.6 Clinical Presentation
- •15.6.1 External-Compression Headache (ECH)
- •15.6.2 External-Traction Headache (ETH)
- •15.7 Management
- •15.7.1 Nonpharmacological Strategies
- •15.7.2 Pharmacological Strategies
- •15.7.3 Patient Education and Awareness
- •15.8 Conclusion
- •References
- •16.1 Introduction
- •16.2 Pathophysiology
- •16.3 Case Presentation
- •16.4 Case Discussion
- •16.6 Diagnostic Algorithm
- •16.7 Management
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Pathophysiology
- •17.3 Case Presentation
- •17.4 Case Discussion
- •17.5 Clinical Characteristics
- •17.6 Diagnosis
- •17.7 Differential Diagnosis
- •17.8 Treatment
- •17.9 Conclusion
- •References
- •18.1 Introduction
- •18.2 Pathophysiology
- •18.3 Case Presentation
- •18.4 Case Discussion
- •18.5 Clinical Presentation
- •18.6 Diagnosis
- •18.7 Differential Diagnosis
- •18.8 Treatment
- •18.9 Conclusion
- •References
- •19.1 Introduction
- •19.2 Pathophysiology
- •19.3 Case Presentation
- •19.4 Case Discussion
- •19.5 Diagnostic Approach
- •19.6 Management
- •19.7 Conclusion
- •References
- •20.1 Introduction
- •20.3 Case Report
- •20.4 Case Discussion
- •20.6 Clinical Presentation
- •20.7 Diagnostic Algorithm
- •20.8 Conclusion
- •References
- •21.1 Introduction
- •21.2 Case Presentation
- •21.3 Clinical Characteristics
- •21.4 Diagnosis
- •21.5 Treatment
- •References
- •22.1 Introduction
- •22.3 Case Presentation 1
- •22.4 Case Discussion
- •22.5 Case Presentation 2
- •22.6 Case Discussion 2
- •22.7 Clinical Characteristics
- •22.8 Diagnostic Workup
- •22.9 Treatment
- •22.10 Prognosis
- •References
- •23.1 Introduction
- •23.2 Pathophysiology
- •23.3 Case Presentation
- •23.4 Case Discussion
- •23.6 Diagnostic Algorithm
- •23.7 Management
- •23.8 Conclusion
- •References
- •24.1 Introduction
- •24.2 Case Presentation
- •24.3 Case Discussion
- •24.4 Pathophysiology
- •24.6 Clinical Characteristics
- •24.8 Treatment Approaches
- •24.10 Conclusion
- •References
- •25.1 Introduction
- •25.2 Case Presentation
- •25.3 Case Discussion
- •25.4 Conclusion
- •References
- •26.1 Introduction
- •26.2 Pathophysiology
- •26.3 Case Presentation
- •26.4 Case Discussion
- •26.5 Clinical Characteristics
- •26.6 Diagnostic Algorithm
- •26.7 Management
- •26.8 Conclusion
- •References
- •27.1 Introduction
- •27.2 Case Presentations
- •27.3 Clinical Characteristics
- •27.4 Discussion
- •27.5 Conclusion
- •References
- •28.1 Introduction
- •28.2 Case Presentation
- •28.3 Case Discussion
- •28.4 Clinical Characteristics
- •28.5 Diagnosis
- •28.6 Conclusion
- •28.7 Key Messages
- •References
- •29.1 Introduction
- •29.2 Pathophysiology
- •29.3 Case Presentation
- •29.4 Clinical Presentation
- •29.5 Diagnosis
- •29.6 Treatment
- •29.7 Conclusion
- •References
- •30.1 Introduction
- •30.2 Clinical Case
- •30.3 Clinical Presentation
- •30.4 Differential Diagnosis
- •30.5 Diagnosis
- •30.6 Treatment
- •30.7 Conclusion
- •References
- •31.1 Introduction
- •31.2 Pathophysiology
- •31.3 Case Presentation
- •31.4 Case Discussion
- •31.5 Clinical Presentation
- •31.7 Conclusion
- •References
- •32.1 Introduction
- •32.2 Pathophysiology
- •32.3 Case Presentation
- •32.4 Case Discussion
- •32.6 Diagnosis
- •32.7 Additional Diagnostic Evaluations
- •32.8 Apply ICHD-3 Diagnostic Criteria [9]
- •32.10 Management
- •32.11 Conclusion
- •References
- •33.1 Introduction
- •33.2 Pathophysiology
- •33.3 Case Presentation
- •33.4 Clinical Characteristics
- •33.5 Diagnostic Algorithm
- •33.6 Treatment
- •33.7 Conclusion
- •References
- •34.1 Introduction
- •34.2 Pathophysiology
- •34.3 Case Presentation
- •34.4 Case Discussion
- •34.6 Diagnostic Algorithm
- •34.7 Treatment
- •34.8 Conclusion
- •References
- •35.1 Introduction
- •35.3 Case Presentation
- •35.4 Case Discussion
- •35.7 Treatment
- •35.7.1 Oxygen Therapy (100% Oxygen)
- •35.8 Conclusion
- •References
- •36.1 Introduction
- •36.2 Pathophysiology
- •36.3 Case Presentation
- •36.5 Diagnostic Algorithm
- •36.6 Treatment
- •36.7 Conclusion
- •References
- •37.1 Introduction
- •37.2 Pathophysiology
- •37.3 Case Presentation
- •37.4 Headache Characteristics
- •37.5 Case Discussion
- •37.6 Treatment
- •37.7 Conclusion
- •References
- •38.1 Introduction
- •38.2 Pathophysiology
- •38.3 Case Presentation
- •38.4 Clinical Presentation
- •38.5 Diagnostic Algorithm
- •38.6 Treatment
- •38.7 Conclusion
- •References
- •39.1 Introduction
- •39.3 Case Presentation
- •39.4 Case Discussion
- •39.6 ICHD-3 Diagnostic Criteria [28]
- •39.6.1 Diagnostic Criteria
- •39.7 Diagnostic Algorithm
- •39.9 Conclusion
- •References
- •40.1 Introduction
- •40.3 Case Presentation
- •40.4 Case Discussion
- •40.5.1 Diagnostic Algorithm
- •40.6 Treatment
- •40.7 Conclusion
- •References
- •41.1 Introduction
- •41.3 Case Presentation
- •41.4 Clinical Presentation
- •41.5 Differential Diagnosis
- •41.6 Conclusion
- •41.7 Key Messages
- •References
- •42.1 Introduction
- •42.2 Pathophysiology
- •42.3 Case Presentation
- •42.5 Case Discussion
- •42.6 Clinical Presentation
- •42.7 Diagnostic Algorithm [9]
- •42.8 Preeclampsia
- •42.9 Eclampsia
- •42.10 Fetal Assessment
- •42.11 Treatment
- •42.12 Antihypertensive Management [8]
- •42.14 Conclusion
- •References
- •43.1 Introduction
- •43.2 Pathophysiology
- •43.3 Case Presentation
- •43.4 Case Discussion
- •43.5 Clinical Manifestations
- •43.6 Diagnosis
- •43.7 Treatment
- •43.8 Conclusion
- •References
- •44.1 Introduction
- •44.2 Pathophysiology
- •44.3 Case Presentation
- •44.4 Case Discussion
- •44.6 Diagnostic Approach
- •44.7 Management
- •44.8 Conclusion
- •References
- •45.1 Introduction
- •45.2 Pathophysiology
- •45.3 Case Presentation
- •45.6 Treatment
- •45.7 Conclusion
- •References
- •46.1 Introduction
- •46.2 Pathophysiology
- •46.3 Case Presentation
- •46.4 Clinical Characteristics
- •46.5 Differential Diagnosis
- •46.6 Treatment
- •46.7 Conclusion
- •References
- •47.1 Introduction
- •47.2 Pathophysiology
- •47.3 Case Presentation
- •47.4 Case Discussion
- •47.5 Clinical Presentations
- •47.6 Diagnostic Algorithm
- •47.7 Differential Diagnosis
- •47.8 Treatment
- •47.9 Conclusion
- •References
- •48.1 Introduction
- •48.2 Pathophysiology
- •48.3 Case Presentation
- •48.4 Case Discussion
- •48.5 Clinical Characteristics
- •48.7 Treatment
- •48.8 Conclusion
- •References
- •49.1 Introduction
- •49.2 Pathophysiology
- •49.3 Case Presentation
- •49.4 Clinical Presentation
- •49.5 Diagnosis
- •49.6 Treatment
- •49.7 Conclusion
- •References
- •50.1 Introduction
- •50.2 Pathophysiology
- •50.3 Case Presentation
- •50.4 Case Discussion
- •50.5 Clinical Characteristics
- •50.6 Diagnosis
- •50.7 Treatment
- •50.8 Conclusion
- •References
- •51.1 Introduction
- •51.2 Case Presentation
- •51.3 Clinical Characteristics
- •51.4 Diagnosis
- •51.5 Treatment
- •51.6 Conclusion
- •References
- •52.1 Introduction
- •52.2 Pathophysiology
- •52.3 Case Presentation
- •52.4 Case Discussion
- •52.5 Clinical Characteristics
- •52.6 Diagnosis
- •52.6.1 Cervicogenic Headache
- •52.6.2 Migraine
- •52.6.3 Neck Pain
- •52.6.4 Demyelinating Lesions
- •52.6.5 Cervical Myelitis
- •52.6.6 Occipital Allodynia
- •52.6.7 Cervical Muscle Spasms
- •52.7 Treatment
- •52.7.2 Acupuncture
- •52.7.3 Transcutaneous Electrical Nerve Stimulations (TENS)
- •52.8 Minimally Invasive Treatment
- •52.8.1 Nerve Blocks
- •52.8.2 Botulinum Toxin A
- •52.8.3 Radio Frequency
- •52.8.4 Occipital Nerve Stimulation
- •52.9 Surgical Treatments
- •52.10 Conclusions
- •References
- •53.1 Introduction
- •53.2 Pathophysiology
- •53.3 Characteristics of Pain
- •53.4 Case Presentation
- •53.5 Case Discussion
- •53.6 Clinical Characteristics
- •53.8 Treatment
- •53.9 Conclusion
- •References
- •54.1 Introduction
- •54.2 Pathophysiology
- •54.3 Case Presentation
- •54.4 Case Discussion
- •54.5 Clinical Characteristics
- •54.6 Diagnostic Algorithm
- •54.7 Management
- •54.8 Conclusion
- •References
- •55.1 Introduction
- •55.2 Pathophysiology
- •55.3 Case Presentation

Chapter 42
Headache Attributed toPreeclampsia
orEclampsia
AndressaReginaGalego andElianaMeireMelhado
42.1 Introduction
This chapter aims to provide a comprehensive exploration of rare headache disorders through practical diagnostic approaches and case-based learning, offering valuable insights for clinicians and researchers.
It is well known that headaches are a condition commonly associated with pregnancy, often as an isolated and benign symptom [1]. However, headaches can also
be a sign of more severe pathologies, such as preeclampsia and eclampsia, which
are signicant complications with substantial morbidity and mortality [1].
Preeclampsia and related hypertensive disorders of pregnancy affect up to 10% of
pregnancies. Neurological complications seen in association with preeclampsia
include seizures (eclampsia), arterial ischemic stroke, reversible cerebral vasoconstriction syndrome (RCVS), posterior reversible encephalopathy syndrome (PRES),
cervical artery dissection, cerebral venous sinus thrombosis, subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) [1]. Of these, ICH is the most
devastating, directly causing up to 70% of deaths from preeclampsia [1].
Preeclampsia, which typically occurs after the 20th week of gestation, is characterized by high blood pressure and the presence of proteinuria, potentially leading
to serious and signicant complications for both the mother and the baby [2, 3].
Eclampsia, on the other hand, results from the progression of preeclampsia, culminating in the presence of seizures, which can lead to maternal and fetal death [2, 3].
Risk factors for the neurovascular complications of preeclampsia include older age,
non-white race, heart disease, chronic hypertension, infections, prothrombotic and
A. R. Galego
Department of Neurology, Base Hospital, São José do Rio Preto, São Paulo, Brazil
E. M. Melhado (
Department of Neurology, UNIFIPA (Padre Albino University Center), Catanduva,
São Paulo, Brazil
Switzerland AG 2026
D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_42
*)
395© The Author(s), under exclusive license to Springer Nature

396
A. R. Galego and E. M. Melhado
hypercoagulable states, and a history of migraine [2, 3]. Migraine is associated with
an increased risk of both hypertensive disorders of pregnancy and maternal
stroke [2, 3].
When discussing headaches attributed to preeclampsia and eclampsia, it refers to
one of the neurological symptoms that can result from both increased blood pressure and endothelial dysfunction [4]. This specic type of headache can vary signicantly in presentation, duration, and characteristics [4]. Therefore, the presence of
headaches during pregnancy should be a warning sign, especially when accompanied by other clinical and laboratory signs and symptoms [4].
Hypertensive disorders during pregnancy are reported to affect approximately
10–20% of pregnancies in the United States [5].
42.2 Pathophysiology
Preeclampsia is a progressive multisystem disorder characterized by the development of hypertension and proteinuria or organ failure after 20weeks of gestation,
during pregnancy, labor, or postpartum [6]. It is believed that a combination of
maternal and fetal/placental factors is the cause [6]. Abnormalities in placental vasculature can lead to relative hypoxia, ischemia, or placental hyperperfusion, resulting in the release of antiangiogenic factors into the maternal circulation, altering the
mother’s systemic endothelial function and causing hypertension and other manifestations of the disease (hematological, neurological, cardiac, pulmonary, renal,
and hepatic) [6].
Preeclampsia can be broadly categorized into two subtypes: early-onset preeclampsia (or placental) and late-onset preeclampsia (or maternal) [7]. Both appear
to have distinct etiologies and phenotypes. In terms of early-onset type, the defective placenta is attributed to the development of preeclampsia [7]. Examination of
the placenta in preeclampsia reveals numerous placental infarcts and arterial sclerosis [7]. This is accompanied by placental hypoperfusion due to altered trophoblastic
invasion and, therefore, placental ischemia [7]. Maternal preeclampsia arises due to
the interplay between a healthy placenta and maternal factors that ultimately lead to
microvascular damage [7]. This may be due to maternal endothelial dysfunction [7].
Since maternal preeclampsia occurs later in the gestational period, it can be managed expectantly until 37weeks of gestation [7]. Maternal preeclampsia occurs
during the later stages of pregnancy, causing little or no change in arterial conversion, thus maintaining placental perfusion [7].
The underlying mechanism of the association between eclampsia and epilepsy is
unclear [6]. However, hypertensive disorders during pregnancy, particularly eclampsia, are associated with impaired cerebral autoregulation, blood–brain barrier disruption, and neuroinammation, which are possible underlying causes for the
formation of cerebral edema [6]. Furthermore, preeclampsia and eclampsia can
result in irreversible subclinical cerebral infarcts found in areas of cerebral edema
[6]. These ndings are signicant and may be linked to the association with an
increased risk of epilepsy in women with preeclampsia and eclampsia [6]. In other

42 Headache Attributed toPreeclampsia orEclampsia
conditions associated with acute brain injury, such as sepsis, a similar association
with late epilepsy has been found [6].
397
42.3 Case Presentation
Patient: MCG, Female, 25years old
Gestational History: Pregnancies in 2018 and 2023
42.4 Clinical History andProgression
First Pregnancy (2018)
• 08-23-2018—Consultation (28weeks gestation)
• History of migraine with aura since childhood, with signicant worsening from
the fourth month of gestation.
• Episodes of right hemicrania, sometimes on the left.
• Aura accompanied by numbness in hands and feet, and blurred vision, lasting up
to 6 hours.
• During the week of consultation: migraine attacks with aura for three consecu-
tive days, associated with nausea, vomiting, photophobia, and phonophobia.
• One episode with temporary hemiplegia and speech difculty.
• Improvement only with hospital medication (Decadron, Dramin, Tramal,
glucose).
• Diagnosis: Migraine with aura aggravated in the second half of pregnancy with-
out hypertensive disorder.
• Management: Pyridoxine hydrochloride 250mg, coenzyme Q10 150mg for pre-
vention and acute treatment: Dipyrone drops + dimenhydrinate for pain.
• 09-24-2018—Consultation (37weeks gestation)
– Reduced frequency of attacks (3 events in the past month: 2 with aura, 1 with-
out aura).
– Preventive formula maintained, physiotherapy recommended.
• 10-25-2018—Consultation
– No attacks in recent weeks.
– Complaints of tension headache for 1 week.
– Foot edema and stretching difculties.
– Advised to discontinue preventive vitamins.
• 11-22-2018—Telephone contact (postpartum)
– Cesarean delivery on 08/11/2018.
– Postpartum headache, with prolonged aura.
– Medication: Dipyrone, ibuprofen 400mg, ondansetron 4mg.

398
A. R. Galego and E. M. Melhado
Second Pregnancy (2023–2024)
• 06-06-2023—Consultation (age 25)
• No preventive medication since 2018.
• Used copper intrauterine device (IUD) in 2019, removed for new pregnancy
attempt.
• Increase in attack frequency last month (1x/week, some severe).
• Attacks without aura: occipital pain with persistent discomfort.
• Attacks with aura: blurred vision, pre-crisis hand paresthesia lasting 30minutes.
• Prescription: Nortriptyline 0 mg/night, Sumax Pro + Meclin 25 mg for pain,
dipyrone 1g for mild pain.
• Signicant improvement observed.
• 01-11-2024—Consultation (15weeks gestation)
– Pregnant at 15weeks using vitamins.
– Return of symptoms: prolonged visual aura (>1 hour), right-sided
paresthesia.
– Episode of migraine with aphasic aura.
– Medications used: Ibuprofen 600mg, dipyrone, tramadol.
– Emotional complaint: Pain impacting conjugal relationship.
– Conducted anesthetic blocks without corticosteroids.
• 01-24-2024—Consultation (17weeks gestation)
– Improvement after block on 11/01, 10 pain-free days.
– Current diagnosis: Migraine with aura, worsening during pregnancy.
– Management: Monitoring, anesthetic blocks as needed, guidance on hydra-
tion and proper nutrition.
– Conducted additional blocks in 03/24 and 05/24.
• 06-30-2024—38weeks—Normal delivery
– In the week prior to delivery, experienced foot edema, persistent nuchal head-
ache without aura, and was hypertensive in obstetric consultation
170/110mmHg.
– Obstetrician prescribed methyldopa, scheduled cesarean for 07/01, but went
into labor on 06/30 with a normal delivery.
– Postpartum, experienced persistent nuchal headache, high blood pressure,
lower limb edema, and proteinuria; diagnosed with late gestational and imme-
diate postpartum preeclampsia, treated with methyldopa and candesartan.
– Despite signicant nuchal pain, migraine was controlled with serial blocks.
– Improvement and recovery observed within a month, followed by cardiologic
monitoring to verify the need for continued antihypertensive therapy. After
90days (October 2024), antihypertensives were discontinued, patient began
physical activity amidst maternal obligations, breastfeeding, and baby care.

42 Headache Attributed toPreeclampsia orEclampsia
399
42.5 Case Discussion
The patient has a history of migraine with and without aura, with signicant worsening during the second half of the rst pregnancy and the rst half of the second
pregnancy. She experienced attacks with focal neurological phenomena, including
transient hemiplegia and aphasia. Preventive treatment was not maintained consistently after the rst delivery, leading to an increased frequency of attacks.
In the second pregnancy, late-onset preeclampsia was observed, requiring intervention. The patient requires neurological monitoring and tailored interventions.
She remains under observation for the frequency of migraine attacks.
42.6 Clinical Presentation
Patients with preeclampsia often present with complaints of new-onset headaches
not explained by any other diagnosis (i.e., a history of headaches or migraines) that
do not respond to medication [8]. This complaint may or may not be accompanied
by additional reports of visual disturbances [8]. Patients may also experience epigastric pain associated with nausea or vomiting [8]. Shortness of breath and a perceived increase in swelling, both worsening compared to baseline pregnancy-related
symptoms, may also be reported [8].
In patients with preeclampsia, the most prevalent indicators in history typically
include the onset of a recent headache resistant to analgesics [8]. Preeclampsia can
be asymptomatic or cause edema or excessive sudden weight gain (>5 lbs per week)
[9]. Non-dependent edema, such as facial and hand edema (rings may no longer t
on ngers), is more specic than dependent edema [8].
Eclampsia manifests as generalized (tonic–clonic) seizures [8].
Preeclampsia with severe features can cause organ damage; these characteristics
may include severe headache, visual disturbances, confusion, hyperreexia, pain in
the epigastric or right hypochondrium region (reecting hepatic ischemia or capsular distension), nausea and/or vomiting, dyspnea [reecting pulmonary edema,
acute respiratory distress syndrome (ARDS), or cardiac dysfunction secondary to
increased afterload], oliguria (reecting decreased plasma volume or acute ischemic tubular necrosis), and, rarely, stroke [8].
Patients presenting with any unique feature or a combination of these complaints
should undergo a thorough physical examination [8]. This begins with an assessment of vital signs, specically blood pressure [8]. Patients with systolic blood pressure (SBP) ≥140mmHg or diastolic blood pressure (DBP) ≥90mmHg should raise
suspicion for preeclampsia [8]. In patients 20weeks gestation or more, blood pressure readings on two occasions at least 4 hours apart should warrant further diagnostic investigation [8].
The recent reevaluation of diagnostic blood pressure readings has expanded to
include sustained hypertensive readings after repeated measurements to allow timely

400
A. R. Galego and E. M. Melhado
intervention with antihypertensive therapy [8]. These blood pressure readings include
SBP ≥160 mmHg or DBP ≥110 mmHg. According to the American College of
Obstetricians and Gynecologists (ACOG), patients previously diagnosed with gestational hypertension presenting with these severe blood pressures should be diagnosed
with preeclampsia with severe features, regardless of other diagnostic criteria [8].
When patients present with dyspnea, auscultation and percussion of the lungs
should be performed to examine pulmonary disturbances [8]. An assessment of
edema should also be completed, specically evaluating areas of dependent edema
(gravity-related), such as the lower extremities, or independent edema, such as in
the face or hands [8].
While preeclampsia often presents with a notable history and physical signs and
symptoms, there are several atypical presentations [8].
42.7 Diagnostic Algorithm [9]
The diagnostic criteria for headaches attributed to preeclampsia or eclampsia are
outlined in the “International Classication of Headache Disorders” (ICHD) under
the following classication:
10. Headache Attributed to Disorder of Homoeostasis
10.3.4 Headache Attributed to Preeclampsia or Eclampsia [9]
Description:
Headache, typically bilateral and pulsating, occurring in women during pregnancy or the immediate puerperium (up to 4 weeks postpartum) with preeclampsia
or eclampsia. It resolves following the resolution of preeclampsia or eclampsia [9].
Diagnostic Criteria:
A. Headache in a woman who is pregnant or in the puerperium, fullling crite-
rion C [9].
B. Preeclampsia or eclampsia has been diagnosed [9].
C. Evidence of causation demonstrated by at least two of the following:
Headache developed in temporal relation to the onset of the preeclampsia or
eclampsia [9].
1. Either or both of the following:
(a) Headache has signicantly worsened in parallel with worsening of the
preeclampsia or eclampsia [9].
(b) Headache has signicantly improved or resolved in parallel with
improvement in or resolution of the preeclampsia or eclampsia [9].
2. Headache has at least two of the following three characteristics:
(a) Bilateral location [9].
(b) Pulsating quality [9]

42 Headache Attributed toPreeclampsia orEclampsia
401
(c) Aggravated by physical activity [9].
D. Not better accounted for by another ICHD-3 diagnosis [9].
Comments:
Preeclampsia and eclampsia appear to involve a strong maternal inammatory
response, with broad systemic immunological activity [9]. A placenta seems essential for their development, although case reports indicate that eclampsia can occur
in the puerperium as well as during pregnancy. Preeclampsia and eclampsia are
multisystem disorders with various forms [9]. Their diagnosis requires hypertension
(>140/90mmHg) documented on two blood pressure readings at least 4 hours apart,
or a rise in diastolic pressure of 15mmHg or systolic pressure of 30mmHg, coupled
with urinary protein excretion >0.3 g/24 hours [9]. Additionally, tissue edema,
thrombocytopenia, and abnormalities in liver function can occur [9].
42.8 Preeclampsia
Preeclampsia is diagnosed with the new onset after 20weeks of gestation of hypertension [blood pressure plus unexplained new-onset proteinuria (>300mg/24hours
or urine protein/creatinine ratio≥0.3) and/or signs of target organ damage] [10].
Proteinuria is dened as >300mg/24hours [10]. The absence of proteinuria in less
precise tests (e.g., urine dipstick tests, urinalysis) does not rule out preeclampsia [10].
In the absence of proteinuria, preeclampsia can be diagnosed if pregnant women
meet diagnostic criteria for new-onset hypertension and exhibit signs of new-onset
target organ damage [10].
Signs or symptoms of target organ damage may include one or more of the following [10]:
• Thrombocytopenia (platelets <100×10^9/L)
Impaired liver function (aminotransferase >2 times normal) not explained by
alternative diagnoses [10].
Severe and persistent right upper quadrant pain or epigastric pain unresponsive
to medications [10].
Renal insufciency (serum creatinine >1.1mg/dL or doubling of serum creatinine in the absence of kidney disease) [10].
Pulmonary edema [10].
New-onset headache unresponsive to medication and unexplained by alternative
diagnoses [10].
Visual disturbances [10].
Other Diagnostic Categories of Preeclampsia Include
(H = hemolysis; EL = evated liver enzymes; LP =low platelet count) (HELLP)
Syndrome: Classied as a severe form of preeclampsia and diagnosed when all of
the following are present [11]: lactate dehydrogenase (LDH) ≥ 600 IU/L;

402
aminotransferases >2 times normal; and platelets <100×10^9/L.HELLP syndrome
may have atypical clinical presentations, with the absence of hypertension or proteinuria in up to 15% of patients [11].
Preeclampsia Superimposed on Chronic Hypertension Diagnosed when a
patient known to have chronic hypertension develops one of the following after
20weeks [12]: new unexplained proteinuria or worsening proteinuria; elevation of
blood pressure above baseline; or signs of target organ damage. Women with chronic
hypertension are at high risk of preeclampsia and should be closely monitored. An
elevated uric acid level suggests a diagnosis of superimposed preeclampsia, rather
than just chronic hypertension [12].
Patients with any type of preeclampsia are at risk of developing eclampsia [8].
Sometimes, eclampsia occurs before the diagnosis of preeclampsia [8].
A. R. Galego and E. M. Melhado
42.9 Eclampsia
Eclampsia is dened as new-onset tonic–clonic, focal, or multifocal seizures without other known causes (e.g., epilepsy, cerebral ischemia or arterial infarction, intracranial hemorrhage, or drug use) [8].
42.10 Fetal Assessment
The fetus is evaluated using non-stress tests or biophysical proles (including the
assessment of amniotic uid volume) and tests that estimate fetal weight [8].
The link between migraine and adverse pregnancy outcomes, especially hypertensive disorders such as gestational hypertension and preeclampsia, may involve
factors like inammation, endothelial dysfunction, and platelet activation [13].
Individuals with migraine often exhibit cardiovascular risk factors, such as obesity
and chronic hypertension, increasing obstetric risks [13]. These adverse outcomes
and migraine are associated with elevated risks of heart disease and ischemic stroke,
suggesting a common etiology [13
pregnancy migraine was associated with 17% higher risks of preterm birth, 28% of
gestational hypertension, and 40% of preeclampsia [13]. Migraine with aura was
more associated with preeclampsia than without aura, while risks of hypertension
and preterm birth were similar regardless of migraine type [13]. Pre-pregnancy
migraine history is a signicant clinical marker of obstetric risk for vascular complications in pregnancies, independent of other established risk factors [13].
Researchers investigated the relationship between gestational hypertension, preeclampsia, and eclampsia with neurological disorders following childbirth [6].
Utilizing data from the National Patient Registry, the study included 648,385
women with no prior history of chronic hypertension or neurological disorders [6].
]. In a study with 30,555 pregnancies, pre-

42 Headache Attributed toPreeclampsia orEclampsia
403
The ndings revealed an increased risk of migraine, headache, epilepsy, sleep disorders, and mental fatigue among women with hypertensive complications during
pregnancy [6]. Compared to normotensive pregnancies, the risk of developing such
conditions was 27% higher for gestational hypertension, 32% for preeclampsia, and
70% for eclampsia [6]. The most pronounced association was between eclampsia
and epilepsy, with a vefold increased risk. Women with preeclampsia and preterm
delivery showed a higher risk of migraine and headache than those with term delivery [6]. The researchers emphasize the need for postpartum follow-up for these
women to identify neurological symptoms early [6]. Given the impact on quality of
life, medical attention is crucial [6]. Future studies are necessary to understand the
mechanisms involved and develop preventive strategies [6]. These ndings justify
additional investigations and underscore the importance of continuous monitoring
of these women for post-gestational hypertension neurological complications [6].
42.11 Treatment
The treatment of preeclampsia begins with early diagnosis and intervention, focusing on adequate blood pressure control and seizure prevention [8]. The denitive
treatment for preeclampsia is delivery [8]. However, the risk of premature delivery
is weighed against gestational age, fetal growth restriction, fetal distress, and the
severity of preeclampsia. Immediate delivery after maternal stabilization (e.g., seizure control, initiation of blood pressure management) is indicated for [8]:
• Gestation of ≥37weeks
• Severe preeclampsia if gestation is ≥34weeks [8]
• Deterioration of renal, pulmonary, cardiac, or hepatic functions (including
HELLP syndrome) [8]
• Concerning results from fetal monitoring or testing [8]
• Eclampsia [8]
Patients with eclampsia or severe preeclampsia are typically admitted to a special maternal care unit or intensive care unit (ICU) [8]. Pregnant women between 34
and <37weeks of gestation who do not require immediate delivery are hospitalized
for assessment, at least initially [8]. If the maternal and fetal state is reassuring,
outpatient treatment is possible, which includes modied activity, blood pressure
measurements, laboratory monitoring, non-stress fetal tests, and medical consultations at least once per week [8]. If no criteria for severe preeclampsia develop,
delivery can occur (e.g., by induction) at 37weeks [8]. In pregnancy with <34weeks,
if delivery can be safely delayed, corticosteroids are administered for 48hours to
accelerate fetal lung maturity [8]. Corticosteroids may be given to some stable
patients after 34weeks and before 36 weeks of gestation if they have not been
administered earlier [8].

404
A. R. Galego and E. M. Melhado
42.12 Antihypertensive Management [8]
Blood pressure control includes immediate antihypertensive management in cases
of severe hypertension (≥160mmHg systolic and/or ≥110mmHg diastolic), along
with maintenance antihypertensive management in the antepartum or postpartum
period, depending on the specic diagnosis of preeclampsia [8]. Antihypertensive
effective medications without adverse effects on the fetus include [8]:
• Beta-blockers, such as labetalol
• Calcium channel blockers, such as nifedipine
• Alpha-2 agonists, such as clonidine
• Vasodilators, such as hydralazine [8]
Commonly used medications for treating severe hypertension include intravenous (IV) labetalol, IV hydralazine, or immediate-release oral nifedipine [8].
Although no evidence suggests a benet of any IV medication as an initial choice
for antihypertensive management, the choice is often dictated by the presence of IV
access at the time of diagnosis, with oral nifedipine favored when IV access is
unavailable [8]. Commonly used medications for maintaining blood pressure
include oral labetalol, extended-release nifedipine, and extended-release clonidine [8].
42.13 Treatment ofEclampsia
Seizures in eclampsia are a medical emergency and require immediate treatment to
prevent maternal and fetal mortality [14]. The management approach should balance immediate support measures, seizure control, prevention of recurrent seizures,
ensuring safe and optimized delivery, and closely monitored postpartum care [14].
Eclampsia treatment Includes [14]:
• Initial Support Measures: Call for assistance, manage seizures, prevent injuries,
ensure airway and oxygenation, and monitor vital signs and conduct laboratory
studies [14].
• Magnesium Sulfate: Preferred over other anticonvulsant treatments for prevent-
ing eclampsia-related seizures [14]. Magnesium sulfate is administered primarily
to prevent further convulsive activities, not to stop the current seizure [14]. The
standard recommended loading dose is 6g IV over 15–20minutes, followed by
a maintenance dose of 2g/hour [14]. In patients without IV access, a loading
dose of 10g intramuscularly, followed by a maintenance dose of 5g intramuscu-
larly every 4 hours, can be used as an alternate regimen [14]. In patients with
contraindications to magnesium sulfate (e.g., myasthenia gravis, hypocalcemia,
renal insufciency, cardiac ischemia, atrioventricular block, or myocarditis),
alternative anticonvulsant therapies (e.g., phenytoin and diazepam) may be con-
sidered [14]. Levetiracetam may be preferable in patients with myasthenia gra-
vis, a condition that can be exacerbated by phenytoin [14].
Соседние файлы в папке Библиотека им академика М.И. Перельмана
